Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/17/2020
Short Title (70 char) Jose F. Cardona, M.D. Hialeah, FL. EIR issued 11/17/2020
FEI Number 3008031588
Firm Name Jose F. Cardona, M.D.
Record Type EIR
State FL
Establishment Type Clinical Investigations
Similar Posts
FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes
The U.S. Food and Drug Administration (FDA) is warning that cases of a rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors.BlendHouse LLC. Reading, PA. EIR issued 02/17/2023
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 02/17/2023
Short Title (70 char) BlendHouse LLC. Reading, PA. EIR issued 02/17/2023
FEI Number 3015728839
Firm Name BlendHouse LLC
Record Type EIR
State PA
Establishment Type ManufacturerKVK-Tech, Inc. Issues Voluntary Nationwide Recall of One Lot of Betaxolol Tablets, USP 10 mg (Batch Number: 17853A) as a Precautionary Measure Due to a Single Foreign Tablet Found During the Line Clearance After the Batch was Packaged
Newtown, Pennsylvania, KVK-Tech, Inc. is voluntarily recalling one lot (Batch Number: 17853A; “the batch”) of Betaxolol Tablets, USP 10 mg, White, Round, film coated biconvex tablets, debossed “K” above bisect “13” on one side and plain on the other side” to the consumer level. The batch was distribBaxter Oncology GmbH – 09/26/2025
Baxter Oncology GmbH – 09/26/2025. Country: Germany. Record Type: 483Avoiding Products Contaminated with Hidden Ingredients
Many products claiming to help with health issues hide dangerous drug ingredients. Get informed about how to avoid contaminated products and their hidden ingredients.ANDA Assessment Program | GDUFA III Performance Goals and Program Enhancements
GDUFA III includes several enhancements to the ANDA assessment process to maximize the efficiency and utility of each assessment cycle. These enhancements aim to reduce the number of assessment cycles and facilitate timely access to safe, effective, high-quality, and affordable generics.